Last reviewed · How we verify
Novo Rapid
At a glance
| Generic name | Novo Rapid |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Bioresorbable Sirolimus-eluting scaffold in de Novo Coronary Artery Lesions (NA)
- A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 Diabetes (PHASE1)
- Hybrid Closed-Loop System in LADA Patients: A Randomized Trial (NA)
- Total-body Glucose Utilization in Obesity (PHASE4)
- STabilization of Atheroma by Lipid-reducing Effect of Drug-Coated Balloon (STABLE-DCB)
- Safety and Efficacy of Drug-Coated Balloon for De-novo Lesions in Patients With Acute Coronary Syndromes (DCB-ACS) (NA)
- Liver Function Abnormalities in Patients With Acute Heart Failure
- Paclitaxel-coated Balloon for Treatment of De-novo Non-complex Coronary Artery Lesions (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Novo Rapid CI brief — competitive landscape report
- Novo Rapid updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI